Quarterly ResultMay 18, 2026, 04:07 PM
Alpha Tau Reports 100% Glioblastoma Control; Q1 Net Loss $22.9M
AI Summary
Alpha Tau Medical reported groundbreaking interim results from its U.S. REGAIN trial in recurrent glioblastoma, demonstrating 100% local disease control and a 67% complete response rate. The company also completed patient enrollment in its U.S. pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma and presented positive pooled data from pancreatic cancer trials. For the first quarter of 2026, Alpha Tau reported a net loss of $22.9 million, with cash and equivalents totaling $80.2 million, providing a strong runway for continued clinical advancement.
Key Highlights
- REGAIN trial in recurrent glioblastoma showed 100% local disease control and 67% complete response rate.
- Completed patient enrollment in U.S. pivotal ReSTART trial for recurrent cutaneous squamous cell carcinoma with 88 patients.
- Pooled pancreatic cancer data presented at DDW 2026 demonstrated 100% local disease control.
- FDA approved IDE supplement to expand IMPACT pancreatic cancer trial to include gemcitabine with Abraxane.
- Cash, cash equivalents, short-term deposits, and restricted deposits totaled $80.2 million as of March 31, 2026.
- Net loss for Q1 2026 was $22.9 million, or $0.26 per share, compared to $8.7 million in Q1 2025.
- Research and Development expenses increased to $11.0 million in Q1 2026 from $7.2 million in Q1 2025.
- Financial expenses, net, were $9.6 million in Q1 2026, primarily due to warrants liability remeasurement.
Price Impact
More from DRTS